SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Safe & Green Holdings Corp. is a design and construction services company, which engages in the provision of code engineered cargo shipping containers. It operates through the following segments: Construction, Medical, Development, and Corporate and Support. The Construction Services segment includes the manufacturing of unit SG ECHO and other modules projects. The Medical segment consists of joint venture COVID-19 laboratory operations. The Development segment focuses on real property development. The Corporate and Support segment includes general corporate expenses such as the executive office, corporate finance, accounting, audit, tax, human resources, risk management, information technology, marketing, and legal groups, corporate overhead, and other items not allocated to any of the company's other segments. The company was founded on December 29, 1993 and is headquartered in Miami, FL.

Safe & Green Holdings Corp

Safe & Green Holdings is trending due to high short interest and a strategic shift towards integrated energy solutions, sparking discussions of a potential short squeeze. The community is debating the stock's volatility, with some urging others to hold strong while others are wary of a potential pump and dump. Bullish investors are comparing it to previous squeeze events.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia's performance post-earnings is sparking mixed reactions, with some questioning if the AI hype is sustainable as the stock struggles to hold gains despite positive results. The community is debating potential accounting issues and the concentration of revenue among a few key customers, while others see this as a temporary dip before a larger rally driven by long-term AI growth. Concerns about valuation, market manipulation, and broader economic headwinds are also fueling the discussion.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending due to rising memory chip prices driven by AI data center demand, with some analysts predicting substantial future growth and a new price target. Community discussions reflect bullish sentiment, but also caution about potential pullbacks after a significant year-to-date increase. Some traders point to technical indicators suggesting it may be overbought in the short-term.

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

MCRB is trending as the community speculates about a potential buyout, with many pointing to Nestle as a likely suitor given past collaborations and recent corporate restructuring. Discussions revolve around the timing of a deal before the end of the year, potential offer prices, and the impact on shareholders. Some traders are expressing skepticism, citing possible pump-and-dump schemes or an upcoming offering.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending due to positive community sentiment fueled by strong earnings and a potential shift to a tech-forward image with a possible move to the Nasdaq. Discussions also revolve around the impact of consumer spending habits, SNAP benefits, and competition with other retailers. The stock is experiencing increased interest and mentions as a key player in the retail sector.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending downwards, sparking debates about whether it's a temporary dip or the start of a longer bear market, as community members analyze support levels and potential bottom prices. Mixed opinions are fueled by discussions of market manipulation, external factors like potential strategic reserves, and comparisons to the performance of traditional markets. Some traders express concern over heavy liquidations, while others remain optimistic about long-term prospects and institutional adoption.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is experiencing significant volatility, driven by reactions to economic data and sector-specific news like NVDA's earnings. Community chatter highlights a struggle between bulls and bears, with many discussing potential bull traps and the impact of AI on the market. Traders are closely watching key support and resistance levels amid uncertainty about future rate cuts.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is experiencing significant volatility, with community discussions focused on potential downside risks and the correlation with Bitcoin's price movements. Bearish sentiment seems to be growing as some traders discuss shorting opportunities and question the company's long-term prospects given its leveraged position in Bitcoin. Others remain bullish, citing oversold conditions and potential for a rebound.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is trending amid volatile crypto markets and a recent downturn, leading to heightened community discussion around unrealized losses and potential bottom prices. Investors are closely watching for a potential announcement regarding staking rewards to support the stock's price, while also debating the influence of analysts like Tom Lee and market factors on BMNR's performance in relation to Ethereum.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending as investors discuss a recent sell-off despite strong earnings, with community members debating whether this presents a buying opportunity or if concerns about profitability and guidance warrant caution. Some are concerned about Waymo and Tesla's presence in the autonomous vehicle space. Others cite low P/E and upcoming catalysts as reasons for bullish sentiment.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pharma ETFs in Spotlight Following Robust Q3 Earnings Results

Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.

4 Reasons to Buy Pharma ETFs Now for a Healthy Portfolio

Pharma's Trump-Pfizer boost sparks momentum, making ETFs PPH, IHE, PJP & XPH attractive for defensive, undervalued growth plays.

Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit

Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.     

White House Press Secretary Karoline Leavitt said on Thursday that President Donald Trump is set to send out letters to 17 pharmaceutical company CEOs in the U.S., including Eli Lilly (LLY), giving them 60 days to address the global pricing disparity of drugs.“Other nations have been free-loading on U.S. innovation for far too long, and it is time they pay their fair share,” said Leavitt, reading out one of the letters, addressed to Eli Lilly CEO David A. Ricks.<a href="http://stocktwits.com/symbol/LLY">Eli Lilly’s stock</a> dipped more than 1% in afternoon trade after the news broke. On Stocktwits, retail sentiment around the pharmaceutical giant remained in ‘bullish’ territory over the past day.Other pharma stocks also took a hit. Moderna (MRNA) extended its downtrend, dipping nearly 7%, AstraZeneca (AZN) slipped more than 3% and Pfizer (PFE) was down over 1%.&nbsp;The warning comes after Trump signed an executive order delivering ‘most favored nation’ prescription drug pricing for U.S. patients in May.The letter alleges that most of the proposals that the Trump administration has received to resolve the issue of drug pricing promised “more of the same, shifting blame, and requesting policy changes that would result in billions of dollars in handouts to the industry.”It outlines that drug makers have 60 days to achieve the following goals:- Extend the ‘most favored nation’ pricing to Medicaid- Guarantee ‘most favored nation’ pricing for newly launched drugs- Return increased revenues abroad to American patients and taxpayers- Provided for direct purchasing at ‘most favored nation’ pricing“But if you refuse to step up, we will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices,” warned the letter, adding that the Trump administration, U.S. Health Secretary Robert Kennedy Jr. and Centers for Medicare and Medicaid Services (CMS) administrator Mehmet Oz stand ready to implement these terms.&nbsp;According to the letter, the companies have till September 29 to comply.&nbsp;The VanEck Pharmaceutical ETF (PPH) dropped more than 2%, while the iShares U.S. Pharmaceutics ETF (IHE) edged 0.8% lower.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sec-chair-unveils-project-crypto-to-back-trump-push-for-us-crypto-dominance/choLhyMRdG4">SEC Chair Unveils ‘Project Crypto’ To Back Trump’s Push For US Crypto Dominance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

Donald Trump gestures during a meeting with British Prime Minister Keir Starmer (not pictured) on July 28, 2025 in Turnberry, Scotland. (Photo by Christopher Furlong/Getty Images)

Trump To Issue 60-Day Warning Letters To Drugmakers Over Pricing 

The U.S. President is expected to send out these letters through his social media platform, Truth Social.

Equity

ETFs on the Move Post U.S.-China Trade Deal

Morgan Stanley’s Wilson addresses 8 key investor questions

Sandoz CEO Richard Saynor has reportedly stated that the proposal to introduce a Europe-wide list price for new medicines is "deeply flawed."Saynor <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/sandoz-ceo-slams-eu-wide-drug-price-proposal-warns-us-tariffs-will-hurt-patient-2025-04-28/">told</a> Reuters that the proposal, put forth by Novartis and Sanofi in a<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/de921b3c-988c-4d60-aca1-def85c70d299"> letter</a> to the Financial Times on Wednesday, overlooks the structural drivers of high drug prices in the United States and will not address global pricing inequities."It made me smile, made me laugh," Saynor said of the proposal.Sanofi and Novartis, in a proposal submitted last week, alleged that European price controls on medicines hinder innovation and proposed a Europe-wide list price for new medicines within the range of U.S. net prices.Saynor believes that the Trump administration will drive down prices for brand-name medicines. Some form of U.S. price reform, he said, is inevitable. &nbsp;However, big pharmaceutical companies should not hike prices in Europe to compensate, he added.U.S. patients have long borne a disproportionate share of costs for innovative medicines, while large drugmakers maintain high margins, the Sandoz CEO argued, citing Amgen’s autoimmune treatment Enbrel, which costs $70,000 per patient per year in the U.S. compared to $7,000 per patient in Europe.Switzerland-based Sandoz makes generic and biosimilar drugs, which are also sold in the U.S.The company's North America President, Keren Haruvi, has been meeting with White House officials nearly every week to discuss pharmaceutical imports and the U.S. reliance on foreign drug production, Saynor said, according to Reuters.Sandoz could be forced to withdraw some products from the U.S. market if significant tariffs are imposed, he added.Earlier this month, Sandoz <a href="https://stocktwits.com/news-articles/markets/equity/sandoz-files-antitrust-lawsuit-against-amgen-seeks-damages/chfCP48Rbac">filed</a> an antitrust lawsuit against Amgen, Inc., (AMGN), alleging that the latter is blocking competition to its drug Enbrel by unlawfully purchasing certain patent rights.Sandoz’s Erelzi is a biosimilar of Amgen’s Enbrel, a medicine used to treat a range of inflammatory diseases.Sandoz alleged that Amgen blocked competition from more cost-effective biosimilar competitors, including Erelzi, which received approval from the U.S. Food and Drug Administration (FDA) in 2016, using certain patent rights to entrench its position in the market.Many Americans could benefit from the cost savings and expanded access resulting from the introduction of high-quality, more affordable biosimilar options, the company said.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/hsbc-double-downgrades-eli-lilly/chQx6M5RbhN">Eli Lilly Stock Gets A Double Downgrade And Price Target Cut By HSBC Over Valuation, Competition Concerns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Swiss pharmaceuticals company Sandoz Group AG logo seen displayed in front of business webpage. (Photo Illustration by Timon Schneider/SOPA Images/LightRocket via Getty Images)

Sandoz CEO Richard Saynor Slams Proposal For Europe-Wide List Price For New Medicines, Says Report

Saynor told Reuters that the proposal, put forth by Novartis and Sanofi in a letter to the Financial Times on Wednesday, overlooks the structural drivers of high drug prices in the United States and will not address global pricing inequities.

Investors are most bearish in 30 years, BofA survey finds

Investing.com -- Investor sentiment has deteriorated to its most bearish point in three decades, according to the latest BofA Global Fund Manager Survey (FMS).

Pharma stocks up on US tariff exemptions but analyst flags a $46B import cost risk

Investing.com -- Pharmaceutical stocks saw brief relief Thursday after U.S. President Donald Trump left drug products off the list of newly announced tariffs. However, industry leaders and analysts cautioned that the sector is not in the clear, as targeted levies may still be on the horizon.

Shares of Xeris Biopharma Inc. surged more than 9.5% on Thursday, reaching their highest level since June 2021, driven by a better-than-expected revenue forecast for 2025 that fueled investor optimism.&nbsp;The rally came despite a slightly wider-than-expected quarterly loss, with retail sentiment increasingly bullish following the earnings release.Xeris reported an adjusted fourth-quarter loss of $0.03 per share, narrowly missing Wall Street expectations of a $0.02 loss.&nbsp;However, revenue for the period was $60.01 million, exceeding the consensus estimate of $58.54 million.&nbsp;The company's full-year guidance emerged as the key driver of market enthusiasm. Xeris expects 2025 revenue of $255 million to $275 million, significantly higher than the $239.77 million analysts had expected.CEO John Shannon described 2024 as an "exceptional" year, as revenue surpassed $203 million to a record high.&nbsp;CFO Steven Pieper said record quarterly revenue of more than $60 million in&nbsp;Q4 contributed to a positive cash flow of $2 million and adjusted&nbsp;earnings before interest, taxes, depreciation, and amortization (EBITDA) of over $8 million.&nbsp;He added that the 2025 revenue outlook represents more than 30% growth at the midpoint.Xeris currently markets three key products: Recorlev for endogenous Cushing's syndrome, Gvoke for severe hypoglycemia, and Keveyis for primary periodic paralysis.&nbsp;It is also advancing a pipeline of development programs, led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, alongside several early-stage programs leveraging its technology platforms.On Stocktwits, sentiment for Xeris turned 'extremely bullish' (89/100) and reached its highest score in a year, with message volume surging by 780% in the 24 hours to Thursday's close.&nbsp;<figure class="image"><img style="aspect-ratio:1316/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/XERS_sentiment_and_message_volume_as_of_March_6_14ecb19082.png" alt="XERS sentiment and message volume as of March 6.png" width="1316" height="302"><figcaption>XERS sentiment and message volume as of March 6 | source: Stocktwits</figcaption></figure>One user noted that the stock's long period of stagnation, "like 40 qtrs in the desert," had finally given way to momentum.&nbsp;<stembedurl>https://stocktwits.com/NobVega/message/607012972</stembedurl>Another speculated about the possibility of a buyout, suggesting that Xeris could attract an acquisition offer by the end of the year.<stembedurl>https://stocktwits.com/Finwizard61/message/607030000</stembedurl>Short interest in Xeris last stood at 6.9%, according to Koyfin data. The company's stock, which was falling after-hours on Thursday, has gained nearly 22% since the start of the year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart on black background. | Image source: Getty Images

Xeris Biopharma Stock Soars To Nearly 4-Year High On Strong 2025 Outlook, Retail Bulls Charge In

The company expects full-year revenue of $255 million to $275 million, significantly higher than the $239.77 million analysts had expected.

XPH
SPDR Pharmaceuticals ETF

Feed

News

Sentiment

Fundamentals

Info

Latest XPH News

XPHSPDR Pharmaceuticals ETF